-
Mashup Score: 13Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes - 2 month(s) ago
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with adv
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
This largest #realworld study to date showed improved outcomes w/ upfront 1L #targetedtherapy (TT) vs. non-TT in advanced #NSCLC w/ actionable driver oncogenes. Timely switching to TT post-biomarker testing had similar outcomes to upfront TT. #lcsm https://t.co/6qXAMIbVqT https://t.co/wd8p3oQIcc